Accueil>>Signaling Pathways>> Neuroscience>> COX>>SC57666

SC57666

Catalog No.GC31960

SC57666 est un inhibiteur sélectif de la COX2 avec une IC50 de 26 nM.

Products are for research use only. Not for human use. We do not sell to patients.

SC57666 Chemical Structure

Cas No.: 158959-32-1

Taille Prix Stock Qté
1mg
252,00 $US
En stock
5mg
504,00 $US
En stock
10mg
855,00 $US
En stock
20mg
1 575,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SC57666 is a selective COX2 inhibitor with an IC50 of 26 nM.

SC57666 inhibits COX2 with an IC50 of 3.2±0.8 nM in CHO cells stably transfected with human COX isozymes, with 1000 fold or more selectivity over COX1 (IC50=6000±1900 nM)[2].

SC57666 has been shown to be orally active (ED50=1.7 mpk) in the adjuvant-induced arthritis model. No gastric lesions are observed in mice after 5 h when SC57666 is administered intragastrically at 600 mpk. No intestinal damage is observed in rats after 72 h when SC57666 is administered intragastrically at 200 mpk[1].

[1]. Reitz DB, et al. Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally activeCOX2 inhibitors. J Med Chem. 1994 Nov 11;37(23):3878-81. [2]. Riendeau D, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17.

Avis

Review for SC57666

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SC57666

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.